NCT03773926 (TNTA) is a NA clinical trial of Neuro-feedback therapy in Tinnitus, sponsored by Zeta Technologies.

Who is sponsoring NCT03773926?

NCT03773926 is sponsored by Zeta Technologies.

What drugs are being tested in NCT03773926?

Interventions in NCT03773926: Neuro-feedback therapy.

What condition does NCT03773926 study?

NCT03773926 studies Tinnitus, Hearing Loss.

Is NCT03773926 still recruiting?

NCT03773926 is currently status unknown. Last updated 12 December 2018.

Last reviewed 2018-12-12 · How we verify

NCT03773926: TNTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuro-feedback Therapy for Treating Tinnitus

Status unknown NA Last updated 12 December 2018

What this trial tests

NA trial testing Neuro-feedback therapy in Tinnitus in 30 participants. Status unknown.

Timeline

28 May 2018

Primary endpoint
15 January 2019

15 January 2019

Quick facts

Lead sponsor	Zeta Technologies
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	28 May 2018
Primary completion	15 January 2019
Estimated completion	15 January 2019
Sites	2 locations across France

Drugs / interventions tested

Neuro-feedback therapy

Conditions studied

Tinnitus — all drugs for Tinnitus →
Hearing Loss — all drugs for Hearing Loss →

Sponsor

Zeta Technologies

Who can join

18 and older, any sex, with Tinnitus or Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neuro-feedback for treating tinnitus seem to be a promising approach to help people suffering from chronic tinnitus. The past studies on this approach suffered interindividual variability in their results. The investigators' current hypothesis is that the variability of the results is the consequences of two possible flaws: lack of appropriate patient selection and lack of support of the patient during the therapy. This study is aimed at testing these hypotheses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A portable neurofeedback device for treating chronic subjective tinnitus: Feasibility and results of a pilot study.
Guillard R, Fraysse MJ, Simeon R, Cervoni T, et al · · 2021 · cited 6× · PMID 33637216 · DOI 10.1016/bs.pbr.2020.08.001

Verify or expand the search:

Other recruiting trials for Tinnitus

Currently open trials in the same condition.

NCT07393880 — Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus · NA · recruiting
NCT07071480 — Noninvasive Therapy for Tinnitus · NA · recruiting
NCT07435298 — Navigated Repetitive TMS for Chronic Tinnitus · NA · recruiting
NCT07158034 — Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation · NA · recruiting
NCT07017998 — External Therapy for Tinnitus Management · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03773926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zeta Technologies
Last refreshed: 12 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03773926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing